Orthocell MD, Paul Anderson, presented at the Canaccord Genuity South-West Connect ASX Showcase today to share the latest news and developments for the Company’s Ortho-ATI™ and CelGro™ platform technologies.
Orthocell’s CelGro™ technology has been featured as one of only four case studies in the recent Australian Regenerative Medicine Therapies report.
Orthocell has been featured in The Market Herald, following our announcement of positive data from a pre-clinical study for anterior cruciate ligament (ACL) reconstruction.
Orthocell has been featured in The Market Herald, following our announcement of patents granted in Canada and Hong Kong for CelGro.
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about passing a key milestone in the OrthoATI™ rotator cuff tendon study.
Orthocell has been featured in The Market Herald, highlighting the follow-up announcement from our OrthoATI™ rotator cuff tendon regeneration study.
Orthocell CEO and Managing Director Paul Anderson speaks to Proactive after announcing a breakthrough tissue engineering study, combining CelGro™ with lymphatic and blood vessel cells to create functional lymphatic tissue, has been published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Orthocell has been featured in The Market Herald, following the publication of our breakthrough tissue engineering study in the peer-reviewed journal “Proceedings of the National Academy of Sciences of the United States of America”.
Orthocell has been featured in The Market Herald, announcing the appointment of Samson Medical Technologies (SMT) as its exclusive distributor for Striate+ across Australia.
Orthocell CEO and Managing Director Paul Anderson spoke with Oriel Morrison as part of Stockhead V-Con Biotechs.